Inactive Instrument

Aradigm Corporation Stock price Nasdaq

Equities

US0385054004

Biotechnology & Medical Research

Sales 2016 195K Sales 2017 14.46M Capitalization 97.3M
Net income 2016 -32M Net income 2017 -10M EV / Sales 2016 73.3 x
Net cash position 2016 9.37M Net Debt 2017 7.91M EV / Sales 2017 7.27 x
P/E ratio 2016
-0.72 x
P/E ratio 2017
-9.3 x
Employees -
Yield 2016 *
-
Yield 2017
-
Free-Float 60.28%
More Fundamentals * Assessed data
Dynamic Chart
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More about the company
  1. Stock
  2. Equities
  3. Stock Aradigm Corporation
  4. Stock Aradigm Corporation - Nasdaq